|Description||MDL 105519, a ligand selective for the glycine binding site of NMDA receptor, was shown that completely inhibited the binding of [3H]glycine to rat brain membranes with a Ki= 10.9±1.4 nM (n= 6). Inhibits [3H]glycine binding to the NMDA receptor with Kd= 3|
|Synonyms||3-[(E)-2-carboxy-2-phenylethenyl]-4,6-dichloro-1H-indole-2-carboxylic acid MDL 105,519 Mdl 105519 CHEMBL180427 (E)-4,6-Dichloro-3-(2-phenyl-2-carboxyethenyl)indole-2-carboxylic acid 161230-88-2 MDL-105519 Lopac-M-216 AC1O7G4O M216_SIGMA Lopac0_000805 C18H|
|Storage||Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -26℃ for long term (months to years).|
|Shelf Life||2 years|
|Boiling Point||601.3±55.0 °C | Condition: Press: 760 Torr|
Apimostinel is a selective partial agonist of an allosteric site of the glycine site of the NMDA receptor complex under investigation by Naurex. Its mechanism o...
LY 235959 is a competitive N-Methyl-D-Aspartate Receptor antagonist originated by Eli Lilly. No development was reported for treatment of Movement disorders in ...
CGP 43487 has been found to be a NMDA receptor antagonist and was once studied about its influenment of dopaminergic function as a supplement in the treatment o...
Ro 25-6981 Maleate
The Maleate salt form of Ro 25-6981 which is a NMDA receptors blocker and has been found to exhibit neuroprotectant activity in vitro and in vivo. IC50: 9 nM.
LY-221501, a piperidine derivative, has been found to be a NMDA receptor antagonist.
QNZ46, a NMDA receptor antagonist, has been studied to have potential effect in some neurological diseases for it works by influencing some amino acids combinat...
Cgp 39653 is a competitive N-Methyl-D-aspartate (NMDA) receptor antagonist. CGP 39653 can selectively bins to the NMDA receptor as an antagonist with high affin...
Dextromethorphan is an approved drug with sedative, dissociative, and stimulant properties. It is a cough suppressant in many over-the-counter cold and cough me...
LY 233536 is a novel competitive N-methyl-D-aspartate (NMDA) receptor antagonist, but few detailed information has been published yet.
GV-196771, an indole derivative, has been found to be a non-opioid analgesic agent which is also a NMDA antagonist binds to glycine-binding site and was once st...
Amantadine is can be used as an antiviral and an antiparkinsonian drug. It is a NMDA receptor antagonist. Amantadine is also a useful building block in organic ...
Orphenadrine Citrate is a skeletal muscle relaxant, it acts in the central nervous system to produce its muscle relaxant effects.
L-701,324 is a selective antagonist at the glycine site of the NMDA glutamate receptor. L-701,324 shows a beneficial action in the animal model of parkinsonian ...
AM-36 is a potent blocker of batrachotoxinin (BTX)-sensitive Na+ channel binding in rat brain homogenates with an IC50 of 0.28 microM. As a unique neuroprotecti...
CGP 31358 is a compound that can bind to a site on the N-methyl-D-aspartate (NMDA) receptor which is coupled to both the transmitter recognition site and the ch...
D-AP7 is a selective NMDA receptor antagonist that inhibits the glutamate binding site and activation of NMDA receptor. It is the 8-Bromo-cGMP and the more acti...
Eliprodil, a NR2B-NMDA receptor antagonist, was found to have neuroprotective activity in study of ischemia.
MDL 105519, a ligand selective for the glycine binding site of NMDA receptor, was shown that completely inhibited the binding of [3H]glycine to rat brain membra...
Rapastinel, a brain penetrable tetrapeptide, could be a partial agonist of NMDA receptor. It was already finished the Phase II trial for acting as an antidepres...
Ro 25-6981, structurally related to ifenprodil and with no affinity for the known binding sites of non-competitive antagonists such as phencyclidine or MK-801, ...